GlaxoSmithKline PLC ADR (GSK) — Long-term Investment Intensity
GlaxoSmithKline PLC ADR (GSK) has a Long-term Investment Intensity of 60.9% as of December 2019. Long-term investments of $64.26 Billion represent 60.9% of total assets of $105.57 Billion. A higher ratio indicates a company with significant capital committed to long-duration strategic positions. Check GlaxoSmithKline PLC ADR cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
LT Investment Intensity
Long-term Investments
Total Assets
Country
GlaxoSmithKline PLC ADR Long-term Investment Intensity (2013–2019)
This chart shows how GlaxoSmithKline PLC ADR's Long-term Investment Intensity has evolved across 7 annual periods from 2013 to 2019. As of December 2019, the intensity stands at 60.9%, reflecting long-term investments of $64.26 Billion against total assets of $105.57 Billion USD. Explore GlaxoSmithKline PLC ADR debt service capacity to assess how comfortably operating cash covers total debt obligations.
Annual Long-term Investment Intensity for GlaxoSmithKline PLC ADR (2013–2019)
The table below presents the year-by-year Long-term Investment Intensity for GlaxoSmithKline PLC ADR from 2013 to 2019, covering 7 annual filings. Each row shows total assets, long-term investments, the intensity percentage, and the change in percentage points compared to the prior year. For market capitalisation and broader financial context, see GSK market cap.
| Year | LT Investment Intensity | LT Investments (USD) | Total Assets | Change (pp) |
|---|---|---|---|---|
| 2019 | 60.9% | $64.26 Billion | $105.57 Billion | ▲ +10.8 pp |
| 2018 | 50.1% | $29.07 Billion | $58.07 Billion | ▼ -22.2 pp |
| 2017 | 72.2% | $40.73 Billion | $56.38 Billion | ▲ +47.5 pp |
| 2016 | 24.7% | $14.60 Billion | $59.08 Billion | ▲ +5.7 pp |
| 2015 | 19.0% | $10.17 Billion | $53.45 Billion | ▲ +15.4 pp |
| 2014 | 3.6% | $1.45 Billion | $40.65 Billion | ▼ 0.0 pp |
| 2013 | 3.6% | $1.53 Billion | $42.09 Billion | — |